Literature DB >> 12710685

PTEN and cancer.

Ramon Parsons1, Laura Simpson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12710685     DOI： 10.1385/1-59259-328-3:147

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


× No keyword cloud information.
  22 in total

Review 1.  Specific PI3K isoform modulation in heart failure: lessons from transgenic mice.

Authors:  Alessandra Ghigo; Fulvio Morello; Alessia Perino; Federico Damilano; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage.

Authors:  Jianfeng Xu; Carl D Langefeld; S Lilly Zheng; Elizabeth M Gillanders; Bao-Li Chang; Sarah D Isaacs; Adrienne H Williams; Kathy E Wiley; Latchezar Dimitrov; Deborah A Meyers; Patrick C Walsh; Jeffrey M Trent; William B Isaacs
Journal:  Hum Genet       Date:  2004-06-05       Impact factor: 4.132

3.  Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells.

Authors:  Jiang-Hong Man; Bing Liang; Yue-Xi Gu; Tao Zhou; Ai-Ling Li; Tao Li; Bao-Feng Jin; Bing Bai; Hai-Ying Zhang; Wei-Na Zhang; Wei-Hua Li; Wei-Li Gong; Hui-Yan Li; Xue-Min Zhang
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

Review 4.  Anti-HER agents in gastric cancer: from bench to bedside.

Authors:  Lorenzo Fornaro; Maurizio Lucchesi; Chiara Caparello; Enrico Vasile; Sara Caponi; Laura Ginocchi; Gianluca Masi; Alfredo Falcone
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

5.  PTEN is a protein tyrosine phosphatase for IRS1.

Authors:  Yuji Shi; Junru Wang; Sarat Chandarlapaty; Justin Cross; Craig Thompson; Neal Rosen; Xuejun Jiang
Journal:  Nat Struct Mol Biol       Date:  2014-05-11       Impact factor: 15.369

Review 6.  Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.

Authors:  Phuong Khanh H Morrow; Francisco Zambrana; Francisco J Esteva
Journal:  Breast Cancer Res       Date:  2009-07-15       Impact factor: 6.466

7.  Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.

Authors:  Zhenbang Chen; Arkaitz Carracedo; Hui-Kuan Lin; Jason A Koutcher; Nille Behrendt; Ainara Egia; Andrea Alimonti; Brett S Carver; William Gerald; Julie Teruya-Feldstein; Massimo Loda; Pier Paolo Pandolfi
Journal:  Sci Signal       Date:  2009-08-18       Impact factor: 8.192

8.  Analyses of tumor-suppressor genes in germline mouse models of cancer.

Authors:  Jingqiang Wang; Cory Abate-Shen
Journal:  Cold Spring Harb Protoc       Date:  2014-08-01

9.  Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Authors:  Christian D Young; Adam D Pfefferle; Philip Owens; María G Kuba; Brent N Rexer; Justin M Balko; Violeta Sánchez; Hailing Cheng; Charles M Perou; Jean J Zhao; Rebecca S Cook; Carlos L Arteaga
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

10.  Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction.

Authors:  Akram Sadeghirizi; Razieh Yazdanparast; Safiyeh Aghazadeh
Journal:  Tumour Biol       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.